Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–785 of 785 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gene Expression Clear all
Completed Not applicable Interventional

NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients

NCT01771705
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Dose adjust group (NFAT)
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Nov 13, 2026, 6:15 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Permeability Factor in Focal Segmental Glomerulosclerosis

NCT00007475
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Plasma exchange, Cyclophosphamide
Procedure · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Nov 13, 2026, 6:15 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Exosomal MicroRNA Expression in Children With Autism Spectrum Disorder

NCT01749670
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
4 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2014 · Synced Nov 13, 2026, 6:15 AM EST
Completed No phase listed Observational

Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy

NCT01953640
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 13, 2026, 6:15 AM EST
Terminated Phase 2 Interventional Results available

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

NCT04524689
View directory record Official record
Conditions
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Interventions
SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Nov 13, 2026, 6:15 AM EST
Recruiting Not applicable Interventional

Pumping to Up Maternal Milk Production for Preterms

NCT06673160
View directory record Official record
Conditions
Breastfeeding, Breastmilk Expression
Interventions
Pumping every 2 hours, breast pumping every 3 hours
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 28 Days
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 13, 2026, 6:15 AM EST
Completed Not applicable Interventional Results available

Cytokine Expression During Radiation for Breast Cancer

NCT00836186
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation therapy
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Nov 13, 2026, 6:15 AM EST
Completed No phase listed Observational

Gene Expression Profiling in Type 1 Diabetes

NCT00330954
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
7 Years to 14 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 5, 2010 · Synced Nov 13, 2026, 6:15 AM EST
Terminated Phase 1 Interventional

A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors

NCT00951158
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Conjugated Linoleic Acid, Conjugated Linoleic Acid
Dietary Supplement · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Nov 13, 2026, 6:15 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial Matrix Metalloproteinases

NCT01469585
View directory record Official record
Conditions
Breakthrough Bleeding
Interventions
Doxycycline
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Nov 13, 2026, 6:15 AM EST
Completed Phase 2 Interventional Results available

68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer

NCT02559115
View directory record Official record
Conditions
Prostate Cancer
Interventions
68Ga-RM2 (RM2), PET/CT Scan
Radiation · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Nov 13, 2026, 6:15 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Re-expression of ER in Triple Negative Breast Cancers

NCT01194908
View directory record Official record
Conditions
Breast Cancer, Breast Tumors, Breast Neoplasms
Interventions
Decitabine, LBH589, Tamoxifen
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Nov 13, 2026, 6:15 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

NCT04471727
View directory record Official record
Conditions
Small-Cell Lung Cancer, Neuroendocrine Carcinoma
Interventions
Gocatamig, Atezolizumab, Ifinatamab Deruxtecan (I-DXd)
Biological
Lead sponsor
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Nov 13, 2026, 6:15 AM EST
Completed No phase listed Observational

Identification and Semi -Quantification of ER/PR Proteins Expression

NCT02654431
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast Cancer patient, Cancer patients
Procedure
Lead sponsor
Applied Spectral Imaging Ltd.
Industry
Eligibility
20 Years to 80 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Nov 13, 2026, 6:15 AM EST
Completed No phase listed Observational

Gene Expression Profiles to Categorize Wilms Tumors

NCT00897637
View directory record Official record
Conditions
Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Stage I Wilms Tumor, Stage II Wilms Tumor, Stage III Wilms Tumor, Stage IV Wilms Tumor, Stage V Wilms Tumor
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
Arcadia, California • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Nov 13, 2026, 6:15 AM EST
Recruiting Phase 4 Interventional

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

NCT05919329
View directory record Official record
Conditions
Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer, Prostate Adenocarcinoma
Interventions
Piflufolastat, PSMA PET/CT Scan, PSMA PET/MRI scan, Biospecimen Collection, Electronic Health Record Review
Drug · Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 13, 2026, 6:15 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Gene Expression Correlates of Post-Traumatic Stress Disorder (PTSD) Symptom Change After EFT (Emotional Freedom Techniques)

NCT01250431
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
EFT (Emotional Freedom Techniques)
Behavioral
Lead sponsor
Soul Medicine Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
Santa Rosa, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Nov 13, 2026, 6:15 AM EST